< Back to latest news & events

Knowledge Hub

G2/24: A new referral to the Enlarged Board seeks to clarify whether a third party who intervened during appeal proceedings can acquire full appellant status

December 2024

In the referring decision, T1286/23, the Board of Appeal referred the following questions to the Enlarged Board of Appeal:

After the withdrawal of all appeals, may the proceedings be continued with a third party who intervened during the appeal proceedings? In particular, may the third party acquire an appellant status corresponding to the status of a person entitled to appeal as a party adversely affected by the decision under appeal?

Background

A third party may intervene[1] in opposition proceedings after the opposition period has expired if proceedings for infringement have been instituted against them, or following a request of the patentee to cease alleged infringement, the third party has instituted proceedings for a declaration of non-infringement. An admissible intervention is treated as an opposition. Accordingly, an intervener’s opposition is not constrained by what has already been filed by the other opponents; the intervener is entitled to rely on fresh grounds, facts, evidence, and arguments despite their opposition being filed outside the 9-month opposition period.

The Referral

The present case concerned Foreo’s patent for an oscillating handheld skin cleanser. An opposition was filed by Beurer and, while the opposition was pending, the patentee threatened a third party, Geske, for patent infringement. Geske tried to intervene, but, as threats for infringement did not constitute proceedings for infringement, the intervention failed.

Geske tried again after filing a request for non-infringement at the Dusseldorf District Court. However, although the suit had been initiated, the Opposition Division noted that, under German law, a declaration for non-infringement only became “pending” upon receipt of the action by the defendant. By the time receipt of the action was acknowledged by Foreo some months later, the opposition had concluded with the maintenance of the patent in amended form.  However, fortunately for Geske, the opponent (Beurer) appealed, allowing Geske to file an admissible intervention during the appeal.

Beurer, however, withdrew its appeal after issuance of the summons. This drew the validity of Geske’s intervention into question, as the Enlarged Board in G3/04 had already decided that, after withdrawal of the sole appeal, proceedings could not be continued by the intervener. The patentee argued that there were no circumstances to suggest that G3/04 was no longer good law.  However, the referring Board disagreed noting that, unlike in common law systems, Enlarged Board of Appeal decisions were only binding on the Board of the referring decision. The referring Board considered a fresh referral to be necessary because the Enlarged Board in G3/04 had taken a purely literal interpretation of the law, without looking at its legislative intent. This was inconsistent with e.g., the travaux préparatoires, which did not appear to limit the status of an intervener to one of a non-appealing opponent but to give the intervener full opponent status. It would be contradictory for a party with full opponent status to lose that status at appeal.

Conclusion

This case is interesting because it seeks to reopen a question already considered by an Enlarged Board. The referring Board also took the opportunity to consider whether the advent of the UPC justified changing the standing of interveners, given that an alternative forum for central revocation was now available. In answering its own question, the referring Board highlighted the advantages in terms of cost and simplicity of EPO appeal procedures compared to court procedures, such as the UPC. In the Board’s view, it could not have been the legislative intent to deprive interveners from the EPO route, since the travaux préparatoires envisaged permitting a party threatened with an infringement action to conduct validity proceedings before the EPO, even where a common court, comparable to the UPC, would also have been available for such actions.

[1] Article 105 EPC


This article was prepared by Partner & Patent Attorney Hsu Min Chung.

Latest updates

Event - 27th February 2026

HGF are sponsors of IQPC Europe 2026

HGF is proud to sponsor IQPC’s Global IP Exchange Europe 2026, an exclusive invite-only forum bringing together senior in-house IP decision makers from across Europe. In a landscape shaped by …

Event details
Event - 23rd - 25th March 2026

HGF are Gold Sponsors of IPBC Europe 2026

HGF are proud sponsors of IPBC Europe 2026, taking place from 23-25 March 2026 at the Pullman Paris Montparnasse. Bringing together patent pioneers, in-house leaders and private practice specialists, IPBC …

Event details
Event - 8th - 11th February 2026

AUTM Meeting 2026

We are attending the AUTM Annual Meeting from 8–11 February, a flagship event bringing together technology transfer professionals from across the globe. AUTM connects innovators, universities, and industry leaders to …

Event details
Event - 3rd February 2026

HGF Brand & Design Conference 2026

Join us on 3rd February 2026 for HGF’s Brand & Design Conference, the must attend event for in-house legal teams, brand leaders, creatives, and innovators shaping the future of IP. …

Event details
Event - 14th January 2026

Seminar on The aftermath of G1/24 - has anything changed?

HGF is hosting a The aftermath of G1/24 – has anything changed? Which will be followed by networking, apero, and snacks. The Seminar will be held on Wednesday, 14th January …

Event details
Event - 24th - 25th November 2025

HGF Partners with 3AF for the P2I2025 Symposium

HGF are pleased to be a partner of P2I2025, the annual symposium organised by the Intellectual Property Commission of the French Aeronautics and Astronautics Association (3AF). The event brings together …

Event details
Event - 18th November 2025

OIS Investor Forum - Jeffries

HGF is proud to be sponsoring the OIS Investor Forum on 18th November. One of the premier gatherings for leaders, innovators, and investors across the healthcare industry. The forum covers …

Event details
Event - 4th November 2025

HGF are Silver Sponsors of LSPN Europe 2025

HGF is proud to be a Silver Sponsor of LSPN Europe 2025, a leading forum dedicated to helping life sciences innovators protect and leverage their intellectual property across the entire …

Event details